Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Strong Q2 for Cipla amid waning generic Nexium impact

This article was originally published in Scrip

Executive Summary

Cipla reported robust growth in the second quarter ended September buoyed by one-off revenues from the US, but the company sought to temper full year top-line expectations in view of the strong showing in the first half.



Related Companies